Clinical Trial Update: Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 [Phase 1]

View source ↗

Summary

Open-label Phase 1 study at Duke University evaluating the safety, tolerability, and efficacy of the oncolytic herpes simplex virus-1 therapy MVR-C5252 in patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• MVR-C5252

Snippet

Sponsor: Duke University | Conditions: Recurrent High Grade Glioma | Phase 1 | Status: RECRUITING